EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases

Jiang, T; Zhang, YC; Li, XF; Zhao, C; Chen, XX; Su, CX; Ren, SX; Yang, N; Zhou, CC

Zhou, CC (reprint author), Tongji Univ, Shanghai Pulm Hosp, Dept Med Oncol, Sch Med, 507 Zheng Min Rd, Shanghai 200433, Peoples R China.; Zhou, CC (reprint author), Tongji Univ, Sch Med, Thorac Canc Inst, 507 Zheng Min Rd, Shanghai 200433, Peoples R China

EUROPEAN JOURNAL OF CANCER, 2019; 121 (): 98

Abstract

Introduction: Previous studies suggested that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKIs) plus bevacizumab could signific......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索